Relmada Therapeutics, Inc.2024财年第三财季实现净利润-21.73百万美元，同比增加1.23%

市场透视2024-11-17

11月17日，Relmada Therapeutics, Inc.（RLMD.US）公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.（RLMD.US）总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484051028?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-17 00:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2484051028","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics, Inc.2024财年第三财季实现净利润-21.73百万美元，同比增加1.23%","media":"市场透视","content":"<html><body><div>\n<p>11月17日，Relmada Therapeutics, Inc.（RLMD.US）公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.（RLMD.US）总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，...</p>\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b\">网页链接</a>\n</div>\n</body></html>","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Relmada Therapeutics, Inc.2024财年第三财季实现净利润-21.73百万美元，同比增加1.23%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics, Inc.2024财年第三财季实现净利润-21.73百万美元，同比增加1.23%\n</h2>\n<h4 class=\"meta\">\n\n\n2024-11-17 00:03 北京时间   <a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b\"><strong>市场透视</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>11月17日，Relmada Therapeutics, Inc.（RLMD.US）公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.（RLMD.US）总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，...</p>\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b","article_id":"2484051028","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2484051028","pubTimestamp":1731773006,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月17日，Relmada Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，流动比率为6.89。机构评级：截至2024年11月17日，当前有4家机构对Relmada Therapeutics, Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为2.00美元，最高目标价为23.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"Relmada Therapeutics, Inc. achieved net profit of-US $21.73 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 1.23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"RLMD":1},"content_text":"11月17日，Relmada Therapeutics, Inc.（RLMD.US）公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.（RLMD.US）总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，流动比率为6.89。机构评级：截至2024年11月17日，当前有4家机构对Relmada Therapeutics, Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为2.00美元，最高目标价为23.00美元。公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。该公司从事开发化学实体的新型药物产品，以解决中枢神经系统疾病治疗方面未得到满足的高度医疗需求。该公司专注于开发esmethadone（d-美沙酮，dextromethadone，REL-1017），一种N-甲基-D-天门冬氨酸（NMDA）受体拮抗剂。其主要候选产品艾司美沙酮是一种用于治疗抑郁症和其他潜在适应症的口服药剂。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484051028"}